Company intelligence / Profile preview

Standard

South San Francisco, California, United States

Ownership: Private
Employees: ~818
Development stage: Other

Overview

Standard BioTools offers established, commercialized platforms for multi-omic analysis, pioneering in mass cytometry (CyTOF) for proteomics, Biomark microfluidic platforms for high-throughput genomics, and SomaScan assay for high-plex proteomics. Their products and services support thousands of peer-reviewed studies, particularly in oncology, immunology, and translational research[1][3][5][7][8][10].

Modalities: DeviceAntibodyAssaysReagent
Industry: Molecular Diagnostics

Partnerships

SomaLogic (now part of Standard BioTools since 2024 merger; SomaScan platform developed by SomaLogic)[7][9]Illumina (agreement for divestiture of SomaLogic business in 2025)[7]

Beyond the preview

Go deeper on Standard.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Standard.

Explore the full profile